Vitamin D3 in Patients With Sickle Cell Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2016-08-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are approximately 90,000 individuals in the United States with sickle cell disease (SCD). Studies have shown that up to 98 percent of patients with Sickle Cell Disease have a vitamin D deficiency, defined as a 25-hydroxyvitamin D level (25(OH)D) less than or equal to 20 ng/mL. As a result, of low bone density, patients may develop osteonecrosis, chronic inflammation and related pain. This study will be coordinated with patients' regularly scheduled visits for medical care and will require patients to submit blood sample at the start of the study and at 3, 6, 9, AND 12 month visits. Patients will also be scheduled for a bone density measurement (DXA scan) at the start of the study and after 12 months of supplementation to assess for any bone re-mineralization. Thus, the main purpose of this study is to find the amount of nutritional vitamin D that needs to be taken by patients with sickle cell disease in order to correct vitamin D deficiency. The study will also test whether vitamin D supplements improve bone health and reduce inflammation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High Dose Vitamin D for Sickle Cell Disease

NCT01331148

Sickle Cell Disease

COMPLETED PHASE2

Daily Vitamin D for Sickle-cell Respiratory Complications

NCT04170348

Sickle Cell Disease Anemia, Sickle Cell Anemia, Hemolytic, Congenital +9 more

COMPLETED PHASE2

Study of Vitamin D in Children With Sickle Cell Disease

NCT01276587

Sickle Cell Disease

COMPLETED PHASE1/PHASE2

Vitamin D for Sickle-cell Respiratory Complications

NCT01443728

Sickle Cell Disease Vitamin D Deficiency Acute Chest Syndrome +2 more

COMPLETED PHASE2

High Dose Vitamin D Supplementation in Children With Sickle Cell Disease

NCT06274203

Sickle Cell Disease Vitamin D Deficiency Health Related Quality of Life +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational cohort study to follow vitamin D levels over time in patients with sickle cell disease receiving doses of vitamin D as part of their clinical care for vitamin D deficiency.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sickle Cell Disease and Vitamin D deficiency

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (18 years and older)
* Diagnosis of sickle cell disease by hemoglobin electrophoresis (HbSS, hematopoietic blood stem cell \[HbSC\], Sickle cell b0 Thalassemia, Sickle cell b+ Thalassemia)
* Able to give informed consent
* Any race/ethnicity/socioeconomic status

Exclusion Criteria

* Pediatric patient (less than 18 years of age)
* Unable to give informed consent
* Untreated primary hyperparathyroidism (ICD9 codes 252.01XX and 252.00XX)
* hypercalcemia (serum calcium level \> 11 mg/dl; ICD9 codes 275.42XX, 259.3XX, 252.00F)
* Pregnancy: a urine pregnancy test, or a serum pregnancy test, will be obtained at the time of enrollment in addition to reviewing the medical record; pregnant patients will be excluded because they should not undergo DXA scanning
* Patients taking atorvastatin, thiazide diuretics and digoxin, which are medications that can interact with vitamin D
* Non-English speakers

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes